UPClytics
ENDE
Sign inStart trial
View all cases

UPC CFI 503/2024

Sep 2, 2024·EP2493466 · NOVEL ANTITUMORAL USE OF CABAZITAXEL

Follow
Case details
Status
Case Closed (Patent revoked)
Action
Counterclaim for revocation
Category
Counterclaim for revocation
Parties
Claimants
Representatives
  • Anja Lunze
Respondents
Representatives
Division
Munich LD
Judges
Technology
  • Chemistry
    Pharmaceuticals
Language
English
First decided
Dec 12, 2025
EPO Opposition
How this compares
The court's record for this kind of case, counted in first-instance rulings. A figure in brackets is the number of rulings a rate rests on.
Patent revokedMedian days to first decision
All UPC37% (34/91)124
Munich LDLockedLocked
Judge Matthias ZigannLockedLocked
Judge Alima ZanaLockedLocked
Judge Tobias PichlmaierLockedLocked

At the UPC: Zentiva Group (15 cases)·Sanofi Group (33 cases)

Start 14-day free trialAlready a user? Sign in
Related cases
All proceedings on this patent

This dispute contains 7 other proceedings

UPC CoA 24/2026·UPC CoA 27/2026·UPC CFI 98/2026·UPC CFI 99/2026·UPC CFI 148/2024 and 2 more

11 other defendants litigating the same or a related patent

UPC CoA 22/2026·UPC CoA 23/2026·UPC CoA 25/2026·UPC CoA 26/2026·UPC CFI 496/2024 and 6 more

Start a free trial to see how each one ended.

More cases: Munich LD·2024

Decisions
  • 2025-12-12
    Infringement ActionPublic

    Summary: The Munich Local Division issued a rectification order under Rule 353 RoP correcting factual errors in a prior decision in the Sanofi v. Stada/Dr Reddy/Zentiva proceedings, including corrections regarding marketing authorisation holders and expert witness attribution.

    Show the legal issues (1)
    • Rectification of decisions Rule 353 RoP
  • 2025-12-12
    Infringement ActionPublic

    Summary: The Munich Local Division found patent EP 2 493 466 (relating to cabazitaxel pharmaceutical formulations) invalid for lack of inventive step in infringement proceedings brought by Sanofi against STADA, Dr. Reddy's and Zentiva entities, dismissing the infringement claims.

    Show the legal issues (4)
    • Inventive step (cabazitaxel formulation)
    • Infringement
    • Pharmaceutical patent
    • Counterclaim for revocation
Documents
Document titleDatePublic
Note2026-03-11Not public
Note2026-02-06Not public
Receipt2026-02-04Not public
Cover sheet2026-02-04Not public
Application document Claimant2026-02-04Not public
Receipt2026-01-12Not public
Cover sheet2026-01-12Not public
Exhibit document Applicant2026-01-12Not public
Exhibit document Applicant2026-01-12Not public
Exhibit document Applicant2026-01-12Not public
Exhibit document Applicant2026-01-12Not public
Application document Applicant2026-01-12Not public
Case closed2025-12-16Not public
Decision2025-12-16Public
Decision2025-12-12Not public
Decision2025-12-12Not public
Other Documents2025-11-25Not public
Cover sheet2025-10-08Not public
Further pleadings2025-10-08Not public
Exhibit2025-10-08Not public
Receipt2025-10-08Not public
Cover sheet2025-10-08Not public
Further pleadings2025-10-08Not public
Exhibit2025-10-08Not public
Receipt2025-10-08Not public
oral hearing reference - IC2025-09-15Not public
oral hearing reference - IC2025-09-15Not public
Fix-Interim-Conference-Date2025-09-10Not public
Interim-Conference-Decision2025-09-10Not public
Written-Procedure-Closure2025-09-10Not public
Acknowledgement-of-lodging2025-08-08Not public
Exhibit No. B.362025-08-08Not public
Exhibit No. B.352025-08-08Not public
Exhibit No. B.322025-08-08Not public
Exhibit No. B.402025-08-08Not public
Exhibit No. B.2.2.22025-08-08Not public
Exhibit No. B.392025-08-08Not public
Exhibit No. 0.52025-08-08Not public
Exhibit No. B.412025-08-08Not public
Rejoinder2025-08-08Not public
Exhibit No. B.422025-08-08Not public
Exhibit No. B.372025-08-08Not public
Exhibit No. B.382025-08-08Not public
Exhibit No. B.432025-08-08Not public
Exhibit No. B.312025-08-08Not public
Exhibit No. B.302025-08-08Not public
Exhibit No. B.2.2.12025-08-08Not public
Exhibit No. B.332025-08-08Not public
Exhibit No. B.342025-08-08Not public
Exhibit No. B.22.1bis2025-08-08Not public
Acknowledgement-of-change-of-a-representative2025-07-10Not public
Acknowledgement-of-lodging2025-07-08Not public
Exhibit_TW_D_14_signed2025-07-08Not public
Exhibit_DFMP_D115_signed2025-07-08Not public
Exhibit_TW_D_16_signed2025-07-08Not public
Exhibit_TW_D_15_signed2025-07-08Not public
Exhibit_DFMP_D114_signed2025-07-08Not public
Exhibit_TW_D_17_signed2025-07-08Not public
2025 07 08 Sanovi vs. Zentiva_ZENTIVA_Rejoinder Infringement_Reply Counterclaim_signed2025-07-08Not public
Application-RoP293-Receipt2025-07-08Not public
Formal-checks_Notification-of-positive-outcome2025-07-08Not public
Application-RoP2932025-06-27Not public
Application2025-06-27Not public
Outcome of the Order2025-05-08Not public
final order2025-05-08Public
final order2025-05-08Not public
Receipt2025-04-11Not public
Exhibit TW D 11_signed2025-04-09Not public
Exhibit TW D 10_signed2025-04-09Not public
Exhibit TW D 12B_373-740_signed2025-04-09Not public
2025 04 09 Sanofi_v_Zentiva_ZENTIVA_Reply to Sanofi Comments No 2 R. 105_signed2025-04-09Not public
Exhibit TW D 12A_1-372_signed2025-04-09Not public
Exhibit TW D 9_signed2025-04-09Not public
Headnote-and-Keywords2025-01-24Not public
Hearing-Dates2025-01-24Not public
scheduling IC and OH for CC2025-01-24Public
Hearing-Dates2025-01-24Not public
Outcome of the Order2025-01-17Not public
R 305 second - final2025-01-17Public
Hearing Reference2025-01-16Not public
Hearing Reference2025-01-16Not public
Hearing-Dates2025-01-13Not public
R 305 second- oral comments2025-01-13Not public
Receipt2025-01-09Not public
Application2025-01-09Not public
Exhibit No. A.02.22025-01-09Not public
Formal-checks_Notification-of-positive-outcome2024-11-01Not public
Acknowledgement-of-lodging2024-11-01Not public
Reply and Defence2024-11-01Not public
Notification Of Service2024-09-30Not public
Zustellnachweis2024-09-30Not public
Acknowledgement of access to case2024-09-25Not public
epoUploadDocumentsWorkflow2024-09-17Not public
Document from EPO2024-09-16Not public
Letter for Service2024-09-04Not public
Panel-Appointment2024-09-04Not public
EPO-Request-for-case-pending2024-09-04Not public
Acknowledgement-of-lodging2024-09-04Not public
Formal-checks_Notification-of-positive-outcome2024-09-04Not public
DFMP P4 - Priority document US 61_3558882024-09-02Not public
DFMP D14 - FDA label for docetaxel (Taxotere) 20072024-09-02Not public
DFMP D29 - Tannock et al.2024-09-02Not public
DFMP P3 - Priority document US 61_3558342024-09-02Not public
DFMP P2 - Priority document US 61_2939032024-09-02Not public
DFMP D112 - Excerpt from the online National Cancer Institute_s Drug Dictionary re. cabazitaxel2024-09-02Not public
TW D 8 - DE Leaflet Cabazitaxel2024-09-02Not public
TW D 5 - FR SMPC Cabazitaxel2024-09-02Not public
DFMP P6 - Priority document US 61_3839332024-09-02Not public
DFMP D111 - INN Publication 20082024-09-02Not public
DFMP D109 - Albarqouni2024-09-02Not public
TW D 7 - DE SMPC Cabazitaxel2024-09-02Not public
TW D 7 - DE SMPC Cabazitaxel2024-09-02Not public
DFMP D90 - Goetz et al.2024-09-02Not public
DFMP D15 - de Bono et al.2024-09-02Not public
DFMP D10 - Sanofi-Aventis Press Release_ 21 December 20092024-09-02Not public
DFMP D9 - Galletti et al.2024-09-02Not public
DFMP D105 - Sava et al.2024-09-02Not public
DFMP D110 - Consolidated List of documents EPO2024-09-02Not public
DFMP D108 - Barraclough and Davis2024-09-02Not public
DFMP P1 - Priority document US 61_2561602024-09-02Not public
TW D 2 - Medicines for Europe2024-09-02Not public
DFMP D26 - Attard et al.2024-09-02Not public
DFMP D11 - Les Echos_ 22 Dec 20092024-09-02Not public
TW D 8 - DE Leaflet Cabazitaxel2024-09-02Not public
DFMP D2 - National Horizon Scanning Centre2024-09-02Not public
DFMP D72 - Scher et al.2024-09-02Not public
DFMP D13 - Pivot et al.2024-09-02Not public
DFMP D35 - Leaflet Aventis Oncology 20032024-09-02Not public
TW D 4 - ANSM Cabazitaxel2024-09-02Not public
TW D 6 - FR Leaflet Cabazitaxel2024-09-02Not public
DFMP D38 - Sanofi Press Release_September 17 20072024-09-02Not public
DFMP P5 - Priority document US 61_3699292024-09-02Not public
TW D 5 - FR SMPC Cabazitaxel2024-09-02Not public
DFMP D18 - EMA Guideline on the Evaluation of Anticancer Medicinal Products in Man 20062024-09-02Not public
DFMP D113 - US Code of Federal Regulations Title 21_Chapter I_Part 3142024-09-02Not public
DFMP D91 - Bissery et al.2024-09-02Not public
DFMP D4 - Mita et al.2024-09-02Not public
DFMP D25 - Correspondence_Lancet_2011_377_121-1222024-09-02Not public
DFMP D7 - Beardsley et al.2024-09-02Not public
DFMP D3a - Blog post by Dr. Barry Mirtsching 12 October 20072024-09-02Not public
DFMP D37 - Winquist et al.2024-09-02Not public
DFMP P7 - Priority document US 61_389,9692024-09-02Not public
2024 09 02 Sanofi vs. Zentiva Statement of Defence and Counterclaim for Revoc2024-09-02Not public
TW D 3 - Report EU Commission2024-09-02Not public
TW D 6 - FR Leaflet Cabazitaxel2024-09-02Not public
DFMP D103 - Fossa. et al.2024-09-02Not public
DFMP D21 - EMA Assessment Report for Jevtana (cabazitaxel) January 20 20112024-09-02Not public
DFMP D3b - Further blog post by Dr. Mirtsching July 6 20072024-09-02Not public
DFMP D104 - Tannock_Clin. Oncol. 19962024-09-02Not public
TW D 4 - ANSM Cabazitaxel2024-09-02Not public
DFMP D102 - Tannock_Clin. Oncol. 19892024-09-02Not public
DFMP D1 - Sanofi-Aventis - XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone2024-09-02Not public
DFMP D11 - Les Echos_ 22 Dec 20092024-09-02Not public